Ginkgo Bioworks (NYSE:DNA) Releases Earnings Results, Misses Estimates By $0.37 EPS

Ginkgo Bioworks (NYSE:DNA) issued its quarterly earnings data on Tuesday. The company reported ($1.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.45) by ($0.37), Zacks reports. Ginkgo Bioworks had a negative net margin of 298.78% and a negative return on equity of 58.54%. Ginkgo Bioworks updated its FY 2025 guidance to EPS.

Ginkgo Bioworks Trading Down 0.9 %

Shares of DNA stock traded down $0.10 during trading on Tuesday, hitting $10.37. The company’s stock had a trading volume of 2,820,512 shares, compared to its average volume of 1,745,475. Ginkgo Bioworks has a 52 week low of $5.26 and a 52 week high of $64.40. The business’s fifty day moving average is $11.50. The company has a market cap of $595.78 million, a P/E ratio of -0.79 and a beta of 1.16.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.